English
Afrikaans
Arabic
Armenian
Chinese (Simplified)
Chinese (Traditional)
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
German
Greek
Hebrew
Hungarian
Icelandic
Italian
Japanese
Korean
Kurdish (Kurmanji)
Latvian
Lithuanian
Luxembourgish
Macedonian
Maltese
Myanmar (Burmese)
Norwegian
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Ukrainian
Vietnamese
Welsh
The recommendation from the EMA’s human drugs committee is good news for the gene therapy field after a string of negative developments. Clinical and regulatory setbacks have weighed on company valuations, limiting their fundraising options and leading to restructuring and layoffs for a number of gene therapy developers.
PTC’s regulatory decision is the first of several expected in the coming months that, if positive, could help turn investors’ views around. After its European disappointment, Bluebird is expecting Food and Drug Administration decisions on its two gene therapies this year, while closely watched projects from BioMarin Pharmaceutical and UniQure could also be under FDA review soon. Likewise, PTC expects by the end of September to ask the FDA for approval of Upstaza.
PTC’s therapy corrects a mutation that disrupts production of an enzyme called aromatic L-amino acid decarboxylase, which is in turn vital to production of other chemicals needed for nervous system signaling. As with Luxturna and Zolgensma, Upstaza uses an adeno-associated virus to deliver the corrected gene into cells.
Click here to read the full article at Biopharma Dive
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.
BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with unmet medical needs. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.